Free Trial

X4 Pharmaceuticals (XFOR) Competitors

X4 Pharmaceuticals logo
$1.82 -0.01 (-0.55%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$1.80 -0.02 (-1.04%)
As of 07/25/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XFOR vs. JATT, CLSD, KZR, CLNN, OKUR, RNTX, FGEN, BDRX, ESLA, and MIRA

Should you be buying X4 Pharmaceuticals stock or one of its competitors? The main competitors of X4 Pharmaceuticals include JATT Acquisition (JATT), Clearside Biomedical (CLSD), Kezar Life Sciences (KZR), Clene (CLNN), OnKure Therapeutics (OKUR), Rein Therapeutics (RNTX), FibroGen (FGEN), Biodexa Pharmaceuticals (BDRX), Estrella Immunopharma (ESLA), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry.

X4 Pharmaceuticals vs. Its Competitors

JATT Acquisition (NYSE:JATT) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

X4 Pharmaceuticals has a consensus target price of $72.33, suggesting a potential upside of 3,874.36%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than JATT Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
JATT Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
X4 Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by insiders. Comparatively, 2.4% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

X4 Pharmaceuticals has a net margin of 46.54% compared to JATT Acquisition's net margin of 0.00%. JATT Acquisition's return on equity of -49.58% beat X4 Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
JATT AcquisitionN/A -49.58% 2.84%
X4 Pharmaceuticals 46.54%-181.56%-54.36%

In the previous week, X4 Pharmaceuticals had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 1 mentions for X4 Pharmaceuticals and 0 mentions for JATT Acquisition. X4 Pharmaceuticals' average media sentiment score of 1.89 beat JATT Acquisition's score of 0.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
JATT Acquisition Neutral
X4 Pharmaceuticals Very Positive

JATT Acquisition has higher earnings, but lower revenue than X4 Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
JATT AcquisitionN/AN/A$6.85MN/AN/A
X4 Pharmaceuticals$2.56M4.12-$37.45M$2.140.85

Summary

X4 Pharmaceuticals beats JATT Acquisition on 8 of the 12 factors compared between the two stocks.

Get X4 Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XFOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XFOR vs. The Competition

MetricX4 PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$10.59M$3.05B$5.70B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E Ratio0.8521.1828.3320.08
Price / Sales4.12282.17430.8989.29
Price / CashN/A42.7636.2258.56
Price / Book0.478.378.675.88
Net Income-$37.45M-$55.19M$3.25B$258.89M
7 Day Performance27.27%5.86%4.23%3.71%
1 Month Performance-9.00%17.29%10.50%11.72%
1 Year Performance-92.96%4.39%34.42%18.00%

X4 Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XFOR
X4 Pharmaceuticals
4.9382 of 5 stars
$1.82
-0.5%
$72.33
+3,874.4%
-93.0%$10.59M$2.56M0.8580Positive News
JATT
JATT Acquisition
N/A$1.91
-2.6%
N/A-54.6%$32.95MN/A0.003High Trading Volume
CLSD
Clearside Biomedical
2.2924 of 5 stars
$0.34
-17.1%
$4.20
+1,138.9%
-56.0%$31.78M$1.66M-0.8330High Trading Volume
KZR
Kezar Life Sciences
4.1212 of 5 stars
$4.30
-1.1%
$39.50
+818.6%
-34.5%$31.78M$7M0.0060
CLNN
Clene
3.4621 of 5 stars
$3.87
+1.3%
$40.00
+933.6%
-18.2%$31.58M$340K0.00100
OKUR
OnKure Therapeutics
3.3887 of 5 stars
$2.32
-0.4%
$32.33
+1,293.7%
N/A$31.48MN/A0.00N/APositive News
RNTX
Rein Therapeutics
N/A$1.44
+1.4%
N/AN/A$31.46MN/A0.009Positive News
Gap Down
FGEN
FibroGen
4.5953 of 5 stars
$7.56
-1.2%
$250.00
+3,206.9%
-75.8%$30.92M$29.62M-3.02570Positive News
BDRX
Biodexa Pharmaceuticals
0.2928 of 5 stars
$0.85
+0.7%
N/AN/A$30.86M$470K0.0020Positive News
ESLA
Estrella Immunopharma
3.2141 of 5 stars
$0.84
-1.5%
$16.00
+1,804.8%
-47.9%$30.86MN/A0.00N/ANews Coverage
Gap Down
MIRA
MIRA Pharmaceuticals
2.5957 of 5 stars
$1.68
-6.7%
$14.00
+733.3%
-43.1%$30.45MN/A0.002

Related Companies and Tools


This page (NASDAQ:XFOR) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners